Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo

Journal of Steroid Biochemistry and Molecular Biology

Volumn 59, Issue 5-6, 1996, Pages 389-396

  Somjen D ^a   Waisman, A ^b   Kaye, A M ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE BB; ESTRADIOL; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; RALOXIFENE; TAMOXIFEN; TAMOXIFEN METHIODIDE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADIPOSE TISSUE CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BONE; CALVARIA; CARDIOVASCULAR DISEASE; CARTILAGE; CELL CULTURE; CONTROLLED STUDY; DIAPHYSIS; EMBRYO; ENZYME ACTIVITY; EPIPHYSIS; ESTROGEN ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; OSTEOBLAST; OSTEOPOROSIS; OSTEOSARCOMA; RAT; TISSUE SPECIFICITY; UTERUS;

ADIPOCYTES; AGE FACTORS; ANIMALS; ANTICARCINOGENIC AGENTS; BIOLOGICAL MARKERS; BONE AND BONES; CARTILAGE; CELLS, CULTURED; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO; EPIPHYSES; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; ISOENZYMES; MALE; OSTEOBLASTS; PIPERIDINES; PUBERTY; RALOXIFENE; RATS; RATS, WISTAR; TAMOXIFEN; UTERUS;

EID: 0030450585     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00135-5     Document Type: Article

References (40)

1. 1. Jordan V. C.: A current view of tamoxifen for the prevention of breast cancer. Br. J. Pharmacol. 110 (1993) 507-517.
2. 2. Wakeling A. E. and Bowler J.: Novel antiestrogen without partial agonist activity. J. Steroid Biochem. 31 (1988) 645-653.
3. 3. Love P. R., Mazess R. B., Barden H. S., Epstein S., Newcomb P. A., Jordan V. C., Carbone P. P. and DeMets D. L.: Effects of tamoxifen on bone mineral density in post-menopausal women with breast cancer. N. Engl. J. Med. 326 (1992) 852-856.
4. 4. Love R. R., Weibe D. A., Newcomb P. A., Cameron L., Leventhal H., Jordan V. C., Feyzi J. and DeMets L.: Effects of tamoxifen on cardiovascular risk factors in post-menopausal women. Ann. Intern. Med. 115 (1991) 860-864.
5. 5. Assikis V. J. and Jordan V. C.: Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int. J. Gynecol. Obstet. 49 (1995) 241-257.
6. 6. Kurl R. N. and Borthwick N. M.: Clomiphene and tamoxifen action in the rat uterus. J. Endocr. 85 (1980) 519-524.
7. 7. Kaye A. M., Brewster M., Degani H., Pop E., Sömjen D. and Biegon A.: A permanently charged tamoxifen derivative displays improved activity and tissue selectivity in rodents (Abstract). 5th International Congress on Hormones and Cancer, Quebec City, 17-20 September, 85 (1995).
8. 8. Phillips S. M. and Sherwin B. B.: Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 17 (1992) 485-495.
9. 9. Phillips S. M. and Sherwin B. B.: Variations in memory function and sex steroid hormones across the menstrual cycle. Psychoneuroendocrinology 17 (1992) 497-506.
10. 10. Fillit H., Weinreb H., Cholst I., Luine V., McEwen B., Amador R. and Zabriskie J.: Observations in a preliminary open trial of estradiol therapy for senile dementia -Alzheimer's type. Psychoneuroendocrinology 11 (1986) 337-345.
11. 11. Reiss N. and Kaye A. M.: Identification of the major component of the estrogen induced protein of rat uterus as the BB isozyme of creatine kinase. J. Biol. Chem. 256 (1981) 5741-5749.
12. 12. Sömjen D., Mor Z. and Kaye A. M.: Age dependence and modulation by gonadectomy of the sex specific response of rat diaphyseal bone to gonadal steroids. Endocrinology 134 (1994) 809-814.
13. 13. Sömjen D., Weisman Y., Harell A., Berger E. and Kaye A. M.: Direct and sex-specific stimulation by sex steroids of creatine kinase activity and DNA synthesis in rat bone. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 3361-3365.
14. 14. Weisman Y., Cassorla F., Malozowski S., Krieg S. J., Goldray D., Kaye A. M. and Sömjen D.: Sex specific response of bone cells to gonadal steroids: Modulation in perinatally androgenized females and testicular feminized male rats. Steroids 58 (1993) 126-133.
15. 15. Majeska R. J., Rodan S. B. and Rodan G. A.: Parathyroid hormone-responsive clonal cell lines from rat osteosarcoma. Endocrinology 107 (1980) 1494-1503.
16. 16. Donahue H. J., McLeod K. J., Rubin C. T., Andersen J., Grine E. A., Hertzberg E. L. and Brink P. R.: Cell to cell communication in osteoblastic networks: cell line dependent hormonal regulation of gap junction function. J. Bone Min. Res. 10 (1995) 881-889.
17. 17. Levy J., Shimshoni Z., Somjen D., Berger E., Fine N., Silberman M. and Binderman I.: Rat epiphyseal cells in culture: responsiveness to bone seeking hormones. In vitro 24 (1988) 620-625.
18. 18. Nishida M., Kasahara K., Kaneko M. and Iwasaki H.: Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Acta Obstet. Gynecol. Jpn 37 (1985) 1103-1110.
19. 19. Sömjen D., Tordjman K., Waisman A., Mor G., Amir-Zaltsman Y., Kohen F. and Kaye A. M.: Expression of estrogen receptors and estrogen responsiveness in 3T3L1 adipocytes after differentiation in culture (Abstract). Annual Meeting of the Endocrine Society, Washington, DC, 14-17 June (1995).
20. 20. Bradford M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt. Biochem. 72 (1976) 248-254.
21. 21. Black L. J., Jones C. D. and Falcone J. F.: Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 32 (1983) 1031-1036.
22. 22. Clemens J. A., Bennett D. R., Black J. and Jones C. D.: Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 32 (1983) 2869-2875.
23. 23. Black L. J., Sato M., Rowley E. R., Magee D. E., Bekele A., Williams D. C., Cullinan D. J., Bendele R., Kauffman R. F., Bensch W. R., Frolik C. A., Termine J. D. and Bryant H. U.: Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93 (1994) 63-69.
24. 24. Evans G., Briant H. U., Magee D., Sato M. and Turner R. T.: The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134 (1994) 2283-2288.
25. 25. Turner C. H., Sato M. and Briant H. U.: Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135 (1994) 2001-2005.
26. 26. Kauffman R. F. and Bryant H. U.: Selective estrogen receptor modulators. Drug News Perspect. 8 (1995) 531-539.
27. 27. Bartell G., Pronzato P., Amoroso D., Cusmano M. P. and Conte P. F.: Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III. Breast Cancer Res. Treat. 12 (1988) 307-310.
28. 28. Dewar J. A., Horobin J. M., Preece P. E., Tavendale R., Tunsale-Pedoe H. and Wood R. A. B.: Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 305 (1992) 225-226.
29. 29. Gottardis M. M., Robinson S. P., Satyaswaroop P. G. and Jordan V. C.: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 44 (1988) 4006-4010.
30. 30. Van Leuwen F. E., Bernaadt J., Coebergh J. W. W., Kiemeney L., Gimbrere C. H. F., Otter R., Schouten L. J., Danhius R. A. M., Bontenbal M., Diepenhorst F. W., Van der Belt-Dusebout A. W. and Van Tintesen H.: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343 (1994) 448-452.
31. 31. Hall T. J., Nyugen H., Schaueblin M. and Fournier B.: The bone-specific estrogen centchroman inhibits osteoclastic bone resorption in vitro. Biochem. Biophys. Res. Commun. 216 (1995) 662-668.
32. 32. Coombes R. C., Haynes B. C., Dowsett M., Quigley M., English J., Judson I. R., Griggs L. J., Potter G. A., MacCaque R. and Jarman M.: Idoxifene: report of a phase I study with patients with metastatic breast cancer. Cancer Res. 55 (1995) 1070-1074.
33. 33. Homesly H. D., Shemana I., Gams R. A. and Herry D. S. et al.: Antiestrogenic potency of toremifene and tamoxifen in post menopausal women. Am. J. Clin. Oncol. 16 (1993) 117-122.
34. 34. Powles T. J., Tillyer C. R., Jones A. L., Ashley S. E., Treleaven J., Davey J. B. and McKinna A.: Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital Pilot Programme. Eur. J. Cancer 26 (1990) 680-684.
35. 35. Henderson M.: Current approaches to breast cancer prevention. Science 259 (1993) 630-631.
36. 36. Toran-Alleran C. D.: Mechanisms of estrogen action during neural development: mediation by interactions with the neurotrophins and their receptors? J. Steroid Biochem. Molec. Biol. 56 (1996) 169-178.
37. 37. Somjen D., Weisman Y., Mor Z., Harell A. and Kaye A. M.: Regulation of proliferation of rat cartilage and bone by sex steroid hormones. J. Steroid Biochem. Molec. Biol. 40 (1991) 717-723.
38. 38. Onante S. A., Tsai S. Y., Tsai M.-J. and O'Malley B. W.: Sequence and characterization of a coactivator for the steroid hormone receptor super family. Science 270 (1995) 1354-1357.
39. 39. Halachmi S., Marden E., Martin G., Mackay H., Abbondanza C. and Brown M.: Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264 (1994) 1455-1458.
40. 40. Cavaillès V., Dauvois S., L'Horset F., Lopez G., Hoare S., Kushner P. J. and Parker M. G.: Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 14 (1995) 3741-3751.